About: Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity
Creator	Perkmann, Thomas Binder, Christoph Hartl, Sylvia Strassl, Robert Aletaha, Daniel »more»
source	MedRxiv
abstract	Background: In the context of the COVID-19 pandemic, numerous new serological test systems for the detection of anti-SARS-CoV-2 antibodies have become available quickly. However, the clinical performance of many of them is still insufficiently described. Therefore we compared three commercial, CE-marked, SARS-CoV-2 antibody assays side by side. Methods: We included a total of 1,154 specimens from pre-COVID-19 times and 65 samples from COVID-19 patients ([≥]14 days after symptom onset) to evaluate the test performance of SARS-CoV-2 serological assays by Abbott, Roche, and DiaSorin. Results: All three assays presented with high specificities: 99.2% (98.6-99.7) for Abbott, 99.7% (99.2-100.0) for Roche, and 98.3% (97.3-98.9) for DiaSorin. In contrast to the manufacturers' specifications, sensitivities only ranged from 83.1% to 89.2%. Although the three methods were in good agreement (Cohen's Kappa 0.71-0.87), McNemar's test revealed significant differences between results obtained from Roche and DiaSorin. However, at low seroprevalences, the minor differences in specificity resulted in profound discrepancies of positive predictability at 1% seroprevalence: 52.3% (36.2-67.9), 77.6% (52.8-91.5), and 32.6% (23.6-43.1) for Roche, Abbott, and DiaSorin, respectively. Conclusion: We find diagnostically relevant differences in specificities for the anti-SARS-CoV-2 antibody assays by Abbott, Roche, and DiaSorin that have a significant impact on the positive predictability of these tests.
has issue date	2020-06-05(xsd:dateTime)
bibo:doi	10.1101/2020.06.04.20117911
has license	medrxiv
sha1sum (hex)	a73a02a9097483e778f6ac110c1477b81aa64dc7
schema:url	https://doi.org/10.1101/2020.06.04.20117911
resource representing a document's title	Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity
resource representing a document's body	covid:a73a02a9097483e778f6ac110c1477b81aa64dc7#body_text
is schema:about of	named entity 'tested positive' named entity 'SARS-CoV-2' named entity 'HKU1' named entity 'coronaviruses' named entity 'medRxiv' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software